Matthews International Capital Management Has Increased Its P T Telekomunikasi Indonesia (TLK) Position, Aratana Therapeutics (PETX) Sentiment Is 0.71

June 8, 2017 - By marketbeat

Matthews International Capital Management Llc increased P T Telekomunikasi Indonesia (TLK) stake by 19.38% reported in 2016Q4 SEC filing. Matthews International Capital Management Llc acquired 446,548 shares as P T Telekomunikasi Indonesia (TLK)’s stock rose 18.87%. The Matthews International Capital Management Llc holds 2.75 million shares with $80.20M value, up from 2.30M last quarter. P T Telekomunikasi Indonesia now has $32.54B valuation. The stock declined 0.31% or $0.1 reaching $32.5 on the news. About 6,747 shares traded. Telekomunikasi Indones (Prsr)Tbk PT-ADR (NYSE:TLK) has risen 27.32% since June 8, 2016 and is uptrending. It has outperformed by 10.62% the S&P500.

Aratana Therapeutics, Inc. is a pet therapeutics firm focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The company has market cap of $250.32 million. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. It currently has negative earnings. The Company’s lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation , appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA).

Matthews International Capital Management Llc decreased Cognizant Technology Solutio (NASDAQ:CTSH) stake by 250,800 shares to 4.23 million valued at $236.84M in 2016Q4. It also reduced China Mobile Limited (NYSE:CHL) stake by 301,940 shares and now owns 5.80M shares. Alibaba Group Hldg Ltd (NYSE:BABA) was reduced too.

Since January 1, 0001, it had 0 insider buys, and 2 sales for $767,255 activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts